A 2nd edition of has now been published by a group of medical decision-making experts known collectively as the 2nd Panel. This is a critical review of the recommendations for how to deal with costs in cost-effectiveness analysis, recommendations that are contained in Chapter 8 of that edition, titled "Estimating Costs and Valuations of Non-Health Benefits in Cost-Effectiveness Analysis," authored primarily but not exclusively by Anirban Basu. This review focuses on the correspondence between the costs in the numerator of the incremental cost-effectiveness ratio (ICER) and what is measured in the denominator of the ICER by the quality-adjusted life years (QALYs). Although it raises a number of issues regarding what is actually being measured in the numerator and denominator of the ICER, it primarily challenges the 2nd Panel's recommendation that the costs of non-health consumption in any additional years of life generated by the intervention in question be accounted for in the numerator, even though no measures of the benefits are included in the QALYs in the denominator. This review is adapted from a review of the entire 2 edition that was sent to the 2 Panel steering committee on January 8, 2016.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157428 | PMC |
| http://dx.doi.org/10.1177/2381468318765162 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drone versus ambulance for blood products transportation: an economic evaluation study.
BMC Health Serv Res
December 2021
Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia.
Background: Medical transportation is an essential step in health care services, and includes ground, air and water transportation. Among the important uses of medical transportation is the delivery of blood products in the event of a clinical emergency. Drone technology is the latest technological advancement that may revolutionize medical transportation globally.
View Article and Find Full Text PDFRadiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Int J Radiat Oncol Biol Phys
October 2019
Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Purpose: Hormone therapy without radiation therapy is considered appropriate for women age 70 or above with low-risk, hormone-positive breast cancer after partial mastectomy. However, some patients may prefer radiation without hormone therapy, for which there is minimal modern data. We modeled the comparative efficacy of aromatase inhibition alone without radiation versus radiation alone without hormone therapy.
View Article and Find Full Text PDFIncorporating Household Spillovers in Cost Utility Analysis: A Case Study Using Behavior Change in COPD.
Int J Technol Assess Health Care
January 2019
Institute of Applied Health Research, University of Birmingham,Birmingham,United Kingdom.
Objectives: It is important to capture all health effects of interventions in cost-utility analyses conducted under a societal or healthcare perspective. However, this is rarely done. Household spillovers (health effects on patients' other household members) may be particularly likely in the context of technologies and interventions to change behaviors that are interdependent in the household.
View Article and Find Full Text PDFCost Recommendations in the Second Edition of : A Review.
MDM Policy Pract
April 2018
Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
A 2nd edition of has now been published by a group of medical decision-making experts known collectively as the 2nd Panel. This is a critical review of the recommendations for how to deal with costs in cost-effectiveness analysis, recommendations that are contained in Chapter 8 of that edition, titled "Estimating Costs and Valuations of Non-Health Benefits in Cost-Effectiveness Analysis," authored primarily but not exclusively by Anirban Basu. This review focuses on the correspondence between the costs in the numerator of the incremental cost-effectiveness ratio (ICER) and what is measured in the denominator of the ICER by the quality-adjusted life years (QALYs).
View Article and Find Full Text PDFCost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer.
J Gastrointest Oncol
June 2018
Division of Radiation Oncology, Chonburi Cancer Hospital, Chonburi, Thailand.
Background: Adjuvant chemotherapy at concurrent time with radiation therapy (RT) or at adjuvant time alone in locally advanced rectal cancer (LARC) is used with several regimens. The cost-utility analysis was conducted to compare administration of two 5-FU regimens and capecitabine in the aspect of provider and societal viewpoint.
Methods: Stage II or III rectal cancer patients who received pre-operative or post-operative concurrent chemoradiotherapy and adjuvant chemotherapy were compared by using decision tree model between (I) 5-FU plus leucovorin (LV) for 5 days per cycle (Mayo Clinic regimen); (II) 5-FU continuous infusion (CI) for 120-h per cycle (CAO/ARO/AIO-94 protocol); (III) standard regimen of capecitabine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!